May 20, 2019
CLS Therapeutics Announces Poster Presentation at the Frontiers in Cancer Immunotherapy

CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “CELL-FREE TUMOR DNA AND NEUTROPHIL EXTRACELLULAR TRAPS AS NOVEL THERAPEUTIC TARGETS FOR PANCREATIC CANCER” at the Frontiers in Cancer Immunotherapy organized by the New York Academy of Sciences May 14-15, 2019, in New York, New York.

Dr. Tetz’s presentation provided an overview of CLS-014, an engineered gene therapy platform addressing unmet need in pancreatic cancer with multiple follow-up extension opportunities. CLS-014 is an AAV vector that targets cell-free DNA, and has the potential for the treatment of solid tumors. The poster presentation also provided an overview of in vivo animal efficacy evaluating CLS-014 for the treatment of pancreatic cancer.

Poster Session Presentation Details:

 

About the CLS Therapeutics:

CLS Translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers, beginning with our first program for pancreatic cancer. PC is the third-leading cause of cancer deaths in the United State with  over  45,000 dying in 2018. It is expected to become the leading cause of cancer mortality already  by 2030. 1-year survival is less than 30%.  5-year survival is less than 8%.

CLS-014 is in silico designed  AAV-based  vector encoding  hyperactive human DNase I transgene cassette. Intravenous injection of the vector with a liver specific promoter leads to long term increase of serum  DNase I activity that cleaves cell-free DNA in the blood and therefore affecting primary tumor growth, metastasis and complications associated with NETosis.

CLS-014  is administered as a single injection with any first-line chemotherapeutic agents.

CLS-Therapeutics presented animal data demonstrating the efficacy of CLS-014 in the treatment of  orthotopic pancreatic  mouse xenograft model. CLS-014 alone, inhibited primary tumor growth and metastasis  and  potentiates nab-paclitaxel.

 

About CLS Therapeutics Inc.

CLS-Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.

Sep 22, 2022

NEW YORK, NY /  September 22, 2022 / CLS Therapeutics,  cancer gene therapy company utilizing a novel therapeutic target, announces that its project  been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.

Apr 01, 2019

NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed) encoding DNase I of the treatment of pancreatic cancer animal model.

Apr 07, 2021

NEW YORK, NY /  April 06, 2021 / CLS Therapeutics,  cancer gene therapy company utilizing a novel therapeutic target, announces presentation at the upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.